Form 4 for CLDX Celldex Therapeutics, Inc.
Accepted 2021-12-10 00:00:00 ET · period of report 2021-12-08 · accession 0001179110-21-010820 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2021-12-10 | 2021-12-08 | CLDX | Cavanaugh Sarah | SVP of Corp Affairs, Admin | M - OptEx | $10.04 | +7,323 | 7,731 | +1,795% | +$73.5K |
| D | 2021-12-10 | 2021-12-08 | CLDX | Cavanaugh Sarah | SVP of Corp Affairs, Admin | S - Sale+OE | $40.00 | -7,323 | 408 | -95% | -$292.9K |
| DM | 2021-12-10 | 2021-12-08 | CLDX | Cavanaugh Sarah | SVP of Corp Affairs, Admin | M - OptEx | $0.00 | -7,323 | 78.5K | -9% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-12-08 | M | A | 1,857 | $9.02 | 2,265 | D | — | — | |
| 2 | Common | Common Stock | 2021-12-08 | S | D | 7,323 | $40.00 | 408 | D | — | — | (F1) The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on September 10, 2021. |
| 3 | Common | Common Stock | 2021-12-08 | M | A | 5,466 | $10.38 | 7,731 | D | — | — | |
| 4 | Derivative | Incentive Stock Option (Right to Buy) | 2021-12-08 | M | D | 1,857 | $0.00 | 11,458 | D | $9.02 · — to 2028-06-13 | 1,857 Common Stock | (F2) 25% vested on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. |
| 5 | Derivative | Incentive Stock Option (Right to Buy) | 2021-12-08 | M | D | 5,466 | $0.00 | 78,534 | D | $10.38 · — to 2030-06-18 | 5,466 Common Stock | (F3) 25% vested on June 18, 2021 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. |